| NCT ID | NCT03488732 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Technical University of Munich |
| Condition | Valvular Heart Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2015-04-01 |
| Primary Completion | 2025-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2015-04-01 with a primary completion date of 2025-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients undergoing transcatheter valvular interventions will be prospectively included into the present registry. Baseline, procedural and follow-up data will be collected and analyzed to adress various issues in the field of percutaneous valvular interventions.
Eligibility Criteria
Inclusion Criteria: \- Severe valvular defect planned for valvular intervention Exclusion Criteria: \- No informed consent
Frequently Asked Questions
Who can join the NCT03488732 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Valvular Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03488732 currently recruiting?
Yes, NCT03488732 is actively recruiting participants. Visit ClinicalTrials.gov or contact Technical University of Munich to inquire about joining.
Where is the NCT03488732 trial being conducted?
This trial is being conducted at München, Germany.
Who is sponsoring the NCT03488732 clinical trial?
NCT03488732 is sponsored by Technical University of Munich. The trial plans to enroll 2,000 participants.